AR071203A1 - Compuesto de trifluorometil-indol-carboxamida, su uso para la fabricacion de un medicamento util para el tratamiento de un trastorno psicotico o deterioro cognitivo y composicion farmaceutica que lo comprende - Google Patents
Compuesto de trifluorometil-indol-carboxamida, su uso para la fabricacion de un medicamento util para el tratamiento de un trastorno psicotico o deterioro cognitivo y composicion farmaceutica que lo comprendeInfo
- Publication number
- AR071203A1 AR071203A1 ARP090101342A ARP090101342A AR071203A1 AR 071203 A1 AR071203 A1 AR 071203A1 AR P090101342 A ARP090101342 A AR P090101342A AR P090101342 A ARP090101342 A AR P090101342A AR 071203 A1 AR071203 A1 AR 071203A1
- Authority
- AR
- Argentina
- Prior art keywords
- carboxamide
- manufacture
- treatment
- pharmaceutical composition
- psychotic disorder
- Prior art date
Links
- 208000028017 Psychotic disease Diseases 0.000 title abstract 2
- 208000010877 cognitive disease Diseases 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 231100000876 cognitive deterioration Toxicity 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- CRCSZJYEZAECJZ-UHFFFAOYSA-N FC(F)(F)C1=C(NC2=CC=CC=C12)C(=O)N Chemical compound FC(F)(F)C1=C(NC2=CC=CC=C12)C(=O)N CRCSZJYEZAECJZ-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuesto de trifluorometil-indol-carboxamida, de formula (1) o una sal del mismo, en la que R1 es hidrogeno o alquilo C1-3; R2 es hidrogeno, halo o ciano; y R3 es el grupo de formula (2) donde Ra es halo, alquilo C1-6, alcoxi C1-6, haloalquilo C1-6, haloalcoxi C1-6 o ciano. Actua como medicamento en la modulacion del receptor nicotinico de acetilcolina (nAChR)alfa7. Uso de dicho compuesto para la fabricacion de un medicamento util para el tratamiento de un trastorno psicotico como ser esquizofrenia o deterioro cognitivo. Composicion farmacéutica que lo comprende.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0807050A GB0807050D0 (en) | 2008-04-17 | 2008-04-17 | Novel compounds |
| GB0810229A GB0810229D0 (en) | 2008-06-04 | 2008-06-04 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071203A1 true AR071203A1 (es) | 2010-06-02 |
Family
ID=40791353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101342A AR071203A1 (es) | 2008-04-17 | 2009-04-16 | Compuesto de trifluorometil-indol-carboxamida, su uso para la fabricacion de un medicamento util para el tratamiento de un trastorno psicotico o deterioro cognitivo y composicion farmaceutica que lo comprende |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8283365B2 (es) |
| EP (2) | EP2279184B1 (es) |
| JP (2) | JP2011516598A (es) |
| KR (2) | KR20100135911A (es) |
| CN (2) | CN102066356B (es) |
| AR (1) | AR071203A1 (es) |
| AU (2) | AU2009237650B2 (es) |
| BR (2) | BRPI0911682A2 (es) |
| CA (2) | CA2721630A1 (es) |
| CL (1) | CL2009000916A1 (es) |
| EA (2) | EA018113B1 (es) |
| ES (2) | ES2392795T3 (es) |
| IL (2) | IL208575A (es) |
| MX (2) | MX2010011359A (es) |
| PE (1) | PE20091724A1 (es) |
| TW (1) | TW201004939A (es) |
| UY (1) | UY31769A1 (es) |
| WO (2) | WO2009127679A1 (es) |
| ZA (2) | ZA201006855B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2784B1 (en) | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 5,3,1 - Triazole substitute derivative |
| JP2011500625A (ja) | 2007-10-18 | 2011-01-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | トリ置換された１，２，４−トリアゾール |
| WO2009097306A1 (en) * | 2008-01-30 | 2009-08-06 | Cephalon, Inc. | Substituted pyridazine derivatives which have histamine h3 antagonist activity |
| NZ587669A (en) | 2008-03-19 | 2011-07-29 | Janssen Pharmaceutica Nv | Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators |
| EP2280945B1 (en) | 2008-05-09 | 2014-09-03 | Janssen Pharmaceutica, N.V. | Trisubstituted pyrazoles as acetylcholine receptor modulators |
| KR20120089190A (ko) * | 2009-04-16 | 2012-08-09 | 프록시머겐 리미티드 | 알파 7 니코틴 아세틸콜린 수용체(ｎＡＣｈＲ)의 인돌 유도체 조절체 |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| GB201012686D0 (en) * | 2010-07-28 | 2010-09-15 | Glaxo Group Ltd | Novel compounds |
| JO3078B1 (ar) * | 2009-11-27 | 2017-03-15 | Janssen Pharmaceutica Nv | مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة |
| US20130310419A1 (en) | 2011-02-03 | 2013-11-21 | Lupin Limited | Pyrrole derivatives used as modulators of alpha7 nachr |
| MA34957B1 (fr) | 2011-02-23 | 2014-03-01 | Lupin Ltd | Derives heteroaryle a titre modulateurs des nachr alpha 7 |
| MX2013010698A (es) * | 2011-03-18 | 2014-02-17 | Novartis Ag | Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson. |
| EP2691368A1 (en) | 2011-03-31 | 2014-02-05 | Lupin Limited | Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease |
| TW201245185A (en) | 2011-04-01 | 2012-11-16 | Lundbeck & Co As H | New positive allosteric modulators of nicotinic acetylcholine receptor |
| US8946432B2 (en) | 2011-07-05 | 2015-02-03 | Lupin Limited | Biaryl derivatives as nAChR modulators |
| EP2822946A1 (en) | 2012-03-06 | 2015-01-14 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| KR20150008891A (ko) * | 2012-05-08 | 2015-01-23 | 앤빌 엘엘씨 | 알파 7 니코틴성 아세틸콜린 수용기 알로스테릭 조절제, 그의 유도체 및 그의 용도 |
| HK1209115A1 (en) * | 2012-10-02 | 2016-03-24 | Sumitomo Dainippon Pharma Co., Ltd. | Imidazole derivative |
| EP2945936A1 (en) | 2012-11-12 | 2015-11-25 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| CN103006642B (zh) * | 2013-01-04 | 2014-10-22 | 中国药科大学 | 一类炔亚甲基吲哚-2-酮类衍生物的用途 |
| EP2945941B1 (en) | 2013-01-16 | 2016-12-07 | Lupin Limited | Pyrrole derivatives as alpha 7 nachr modulators |
| JP2016512225A (ja) | 2013-03-13 | 2016-04-25 | ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ | アルファー７ｎａｃｈｒモジュレータとしてのピロール誘導体 |
| US10058310B2 (en) | 2013-03-13 | 2018-08-28 | Ethicon Llc | Electrosurgical device with drum-driven articulation |
| TW201446243A (zh) | 2013-06-03 | 2014-12-16 | Lupin Ltd | 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑 |
| AU2014282886A1 (en) | 2013-06-17 | 2015-12-17 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
| EP3122187A4 (en) * | 2014-03-25 | 2017-11-15 | Emicipi LLC | Treatment of rett syndrome |
| JP6870304B2 (ja) * | 2016-12-05 | 2021-05-12 | 住友電気工業株式会社 | 半導体装置の製造方法 |
| US11046683B2 (en) | 2016-12-15 | 2021-06-29 | Ono Pharmaceutical Co., Ltd. | Activator of TREK (TWIK RElated K+ channels) channels |
| HU231478B1 (hu) | 2018-07-13 | 2024-02-28 | Richter Gedeon Nyrt. | Szubsztituált (aza)indol származékok |
| HU231333B1 (hu) | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirokromán származékok |
| HU231414B1 (hu) | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Tiadiazin származékok |
| AU2020394867A1 (en) | 2019-12-02 | 2022-05-26 | Storm Therapeutics Limited | Polyheterocyclic compounds as METTL3 inhibitors |
| CN111285792B (zh) * | 2020-03-23 | 2023-05-02 | 三峡大学 | 2-取代吲哚化合物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9903997D0 (sv) | 1999-11-03 | 1999-11-03 | Astra Ab | New compounds |
| GB0403155D0 (en) * | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
| KR20100124272A (ko) * | 2008-02-07 | 2010-11-26 | 아보트 러보러터리즈 | 양성 알로스테릭 조절제로서의 아미드 유도체 및 이의 사용방법 |
-
2009
- 2009-04-16 AU AU2009237650A patent/AU2009237650B2/en not_active Ceased
- 2009-04-16 MX MX2010011359A patent/MX2010011359A/es active IP Right Grant
- 2009-04-16 BR BRPI0911682A patent/BRPI0911682A2/pt not_active IP Right Cessation
- 2009-04-16 UY UY031769A patent/UY31769A1/es not_active Application Discontinuation
- 2009-04-16 CA CA2721630A patent/CA2721630A1/en not_active Abandoned
- 2009-04-16 PE PE2009000537A patent/PE20091724A1/es not_active Application Discontinuation
- 2009-04-16 JP JP2011504457A patent/JP2011516598A/ja not_active Ceased
- 2009-04-16 AU AU2009237649A patent/AU2009237649B2/en not_active Ceased
- 2009-04-16 ES ES09732038T patent/ES2392795T3/es active Active
- 2009-04-16 CN CN200980123025.8A patent/CN102066356B/zh not_active Expired - Fee Related
- 2009-04-16 MX MX2010011358A patent/MX2010011358A/es active IP Right Grant
- 2009-04-16 BR BRPI0910585A patent/BRPI0910585A2/pt not_active IP Right Cessation
- 2009-04-16 US US12/936,408 patent/US8283365B2/en not_active Expired - Fee Related
- 2009-04-16 JP JP2011504458A patent/JP2011516599A/ja not_active Ceased
- 2009-04-16 EA EA201071201A patent/EA018113B1/ru not_active IP Right Cessation
- 2009-04-16 KR KR1020107025698A patent/KR20100135911A/ko not_active Withdrawn
- 2009-04-16 EA EA201071202A patent/EA017726B1/ru not_active IP Right Cessation
- 2009-04-16 EP EP09733402A patent/EP2279184B1/en active Active
- 2009-04-16 CN CN200980123031.3A patent/CN102066357B/zh not_active Expired - Fee Related
- 2009-04-16 CL CL2009000916A patent/CL2009000916A1/es unknown
- 2009-04-16 EP EP09732038A patent/EP2279183B1/en active Active
- 2009-04-16 US US12/936,431 patent/US8377941B2/en not_active Expired - Fee Related
- 2009-04-16 KR KR1020107025697A patent/KR20100133016A/ko not_active Withdrawn
- 2009-04-16 CA CA2725441A patent/CA2725441C/en not_active Expired - Fee Related
- 2009-04-16 AR ARP090101342A patent/AR071203A1/es not_active Application Discontinuation
- 2009-04-16 WO PCT/EP2009/054495 patent/WO2009127679A1/en not_active Ceased
- 2009-04-16 ES ES09733402T patent/ES2392796T3/es active Active
- 2009-04-16 WO PCT/EP2009/054493 patent/WO2009127678A1/en not_active Ceased
- 2009-04-16 TW TW098112580A patent/TW201004939A/zh unknown
-
2010
- 2010-09-27 ZA ZA2010/06855A patent/ZA201006855B/en unknown
- 2010-09-27 ZA ZA2010/06856A patent/ZA201006856B/en unknown
- 2010-10-07 IL IL208575A patent/IL208575A/en not_active IP Right Cessation
- 2010-10-07 IL IL208574A patent/IL208574A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071203A1 (es) | Compuesto de trifluorometil-indol-carboxamida, su uso para la fabricacion de un medicamento util para el tratamiento de un trastorno psicotico o deterioro cognitivo y composicion farmaceutica que lo comprende | |
| AR068369A1 (es) | Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina" | |
| MX2010012298A (es) | Activadores de glucocinasa. | |
| EA201170772A1 (ru) | Органические соединения | |
| AR059977A1 (es) | Compuesto de ciclohexil piperidinil dihidrobenzimidazol composicion farmaceutica que lo comprende su uso para la preparacion de un medicamento proceso para preparalo y compuesto intermediario para la sintesis del mismo | |
| AR110128A2 (es) | Compuesto del grupo de las 3-(imidazoil)-pirazolo[3,4-b]piridinas, composición farmacéutica que lo comprende y método para preparar el mismo | |
| BRPI0911208A2 (pt) | moduladores inflamatórios antioxidantes: ácido oleanólico derivados com saturação no c-anel. | |
| EA201001205A1 (ru) | Соединения, содержащие циклобутоксигруппу | |
| CO6630189A2 (es) | Compuestos heterocíclicos de nitrógeno útiles como inhibidores de pde10 | |
| UY32098A (es) | Heteroarilos sustituidos | |
| AR064736A1 (es) | Agonistas de gpcr | |
| EA200971143A1 (ru) | Бензамидные mglur5 позитивные аллостерические модуляторы и способы их получения и применения | |
| CR10992A (es) | Preparacion solida que comprende alogliptina y pioglitazona | |
| AR072263A1 (es) | Compuestos pirido-pirimidina que inhiben mtor composiciones farmaceuticas que los comprenden procesos para su preparacion y su uso como un medicamento | |
| UA109290C2 (uk) | Спільні кристали і солі інгібіторів ccr3 | |
| CO6390058A2 (es) | Piperidina espiro pirrolidinona y piperidinona sustituidas usadas como moduladores de h3 | |
| CL2008003472A1 (es) | Compuestos derivados de 5-[3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-ona, proceso para la preparacion de los mismos, compuestos intermediarios, composicion farmaceutica que comprende dicho compuesto; combinacion farmaceutica, y sus usos en el tratamiento de enfermedades inflamatorias. | |
| AR059839A1 (es) | Compuesto derivado de diazaespiro-acetamida, composicion farmaceutica que lo comprende, uso para la preparacion de un medicamento para el tratamiento de un trastorno mediado por glyt1 y proceso para su preparacion | |
| EA201001855A1 (ru) | Соединения, содержащие циклобутоксигруппу | |
| ECSP099602A (es) | Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas | |
| ECSP10010578A (es) | Composicion farmaceutica 271 | |
| CL2009001089A1 (es) | Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| UY30740A1 (es) | Nuevo procedimiento para la preparacion de 4,4??-( 1-metil-1,2-etandilil)-bis-(2,6-piperazindiona) | |
| AR056369A1 (es) | Compuestos derivados de quinazolina y composicion farmaceutica | |
| BRPI0615614A2 (pt) | compostos orgánicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |